Equities research analysts forecast that Intrexon Corp (NASDAQ:XON) will announce $32.16 million in sales for the current quarter, according to Zacks. Two analysts have issued estimates for Intrexon’s earnings. The lowest sales estimate is $31.51 million and the highest is $32.80 million. Intrexon reported sales of $32.45 million in the same quarter last year, which would suggest a negative year over year growth rate of 0.9%. The business is expected to report its next earnings results on Thursday, November 14th.
According to Zacks, analysts expect that Intrexon will report full-year sales of $124.66 million for the current financial year, with estimates ranging from $122.21 million to $127.10 million. For the next financial year, analysts forecast that the company will report sales of $64.51 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that that provide coverage for Intrexon.
Intrexon (NASDAQ:XON) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.30) by $0.05. The company had revenue of $35.99 million during the quarter, compared to analyst estimates of $29.62 million. Intrexon had a negative return on equity of 31.89% and a negative net margin of 368.47%. The firm’s quarterly revenue was down 20.6% on a year-over-year basis. During the same quarter last year, the company earned ($0.51) earnings per share.
Several equities research analysts have issued reports on XON shares. Bank of America dropped their price target on Intrexon from $7.00 to $6.00 and set an “underperform” rating for the company in a research note on Friday, August 9th. Northland Securities reaffirmed a “hold” rating and set a $10.00 price target on shares of Intrexon in a research note on Monday, August 12th. BidaskClub lowered Intrexon from a “buy” rating to a “hold” rating in a research note on Tuesday, August 6th. Finally, ValuEngine raised Intrexon from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $17.00.
XON stock traded up $0.01 during mid-day trading on Friday, hitting $5.71. 18,684 shares of the stock were exchanged, compared to its average volume of 1,021,934. The company has a debt-to-equity ratio of 0.90, a current ratio of 3.55 and a quick ratio of 3.20. The firm’s fifty day simple moving average is $5.95. Intrexon has a 12 month low of $3.95 and a 12 month high of $16.44. The company has a market cap of $925.42 million, a PE ratio of -4.16 and a beta of 2.35.
In other news, insider Helen Sabzevari sold 8,484 shares of Intrexon stock in a transaction dated Thursday, July 18th. The stock was sold at an average price of $7.47, for a total value of $63,375.48. Following the transaction, the insider now owns 70,825 shares in the company, valued at $529,062.75. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In the last quarter, insiders sold 16,663 shares of company stock worth $108,360. Company insiders own 44.00% of the company’s stock.
Large investors have recently made changes to their positions in the stock. Third Security LLC boosted its position in Intrexon by 10.0% during the 2nd quarter. Third Security LLC now owns 74,553,246 shares of the biotechnology company’s stock valued at $571,078,000 after acquiring an additional 6,762,077 shares in the last quarter. First Trust Advisors LP boosted its position in Intrexon by 72.6% during the 1st quarter. First Trust Advisors LP now owns 11,227,790 shares of the biotechnology company’s stock valued at $59,058,000 after acquiring an additional 4,721,782 shares in the last quarter. Vanguard Group Inc. boosted its position in Intrexon by 33.8% during the 2nd quarter. Vanguard Group Inc. now owns 6,672,135 shares of the biotechnology company’s stock valued at $51,109,000 after acquiring an additional 1,686,028 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. boosted its position in Intrexon by 138.9% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,704,014 shares of the biotechnology company’s stock valued at $20,713,000 after acquiring an additional 1,572,077 shares in the last quarter. Finally, Nikko Asset Management Americas Inc. boosted its position in Intrexon by 133.9% during the 2nd quarter. Nikko Asset Management Americas Inc. now owns 2,704,014 shares of the biotechnology company’s stock valued at $20,713,000 after acquiring an additional 1,548,194 shares in the last quarter. Institutional investors own 75.73% of the company’s stock.
Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.
Recommended Story: Institutional Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.